These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22860991)

  • 41. Investigational melatonin receptor agonists.
    Hardeland R
    Expert Opin Investig Drugs; 2010 Jun; 19(6):747-64. PubMed ID: 20408738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Juvenile hormones, reality or myth?].
    Vermeulen A
    Verh K Acad Geneeskd Belg; 1997; 59(1):19-33. PubMed ID: 9221619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Corneal cell culture models: a tool to study corneal drug absorption.
    Dey S
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):529-32. PubMed ID: 21500964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Jet lag: therapeutic use of melatonin and possible application of melatonin analogs.
    Srinivasan V; Spence DW; Pandi-Perumal SR; Trakht I; Cardinali DP
    Travel Med Infect Dis; 2008; 6(1-2):17-28. PubMed ID: 18342269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The endogenous melatonin (MT) signal facilitates reentrainment of the circadian system to light-induced phase advances by acting upon MT2 receptors.
    Pfeffer M; Rauch A; Korf HW; von Gall C
    Chronobiol Int; 2012 May; 29(4):415-29. PubMed ID: 22489607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Melatonin in diseases of the oral cavity.
    Gómez-Moreno G; Guardia J; Ferrera MJ; Cutando A; Reiter RJ
    Oral Dis; 2010 Apr; 16(3):242-7. PubMed ID: 19682319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ocular melatonin rhythms in teleost fish.
    Iigo M; Furukawa K; Nishi G; Tabata M; Aida K
    Brain Behav Evol; 2007; 69(2):114-21. PubMed ID: 17230019
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of melatonin in cancer treatment.
    Cutando A; López-Valverde A; Arias-Santiago S; DE Vicente J; DE Diego RG
    Anticancer Res; 2012 Jul; 32(7):2747-53. PubMed ID: 22753734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical uses of melatonin: evaluation of human trials.
    Sánchez-Barceló EJ; Mediavilla MD; Tan DX; Reiter RJ
    Curr Med Chem; 2010; 17(19):2070-95. PubMed ID: 20423309
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Therapeutic Trip of Melatonin Eye Drops: From the Ocular Surface to the Retina.
    Rusciano D; Russo C
    Pharmaceuticals (Basel); 2024 Mar; 17(4):. PubMed ID: 38675402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic Effects of Melatonin on Ocular Diseases: Knowledge Map and Perspective.
    Yu H; Wang Q; Wu W; Zeng W; Feng Y
    Front Pharmacol; 2021; 12():721869. PubMed ID: 34795578
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of Daily Melatonin Supplementation on Visual Loss, Circadian Rhythms, and Hepatic Oxidative Damage in a Rodent Model of Retinitis Pigmentosa.
    Fuentes-Broto L; Perdices L; Segura F; Orduna-Hospital E; Insa-Sánchez G; Sánchez-Cano AI; Cuenca N; Pinilla I
    Antioxidants (Basel); 2021 Nov; 10(11):. PubMed ID: 34829724
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.
    Cheng KJ; Hsieh CM; Nepali K; Liou JP
    J Med Chem; 2020 Oct; 63(19):10533-10593. PubMed ID: 32482069
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic potential of melatonin in oral medicine and periodontology.
    Najeeb S; Khurshid Z; Zohaib S; Zafar MS
    Kaohsiung J Med Sci; 2016 Aug; 32(8):391-6. PubMed ID: 27523451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of cathepsins in ocular physiology and pathology.
    Im E; Kazlauskas A
    Exp Eye Res; 2007 Mar; 84(3):383-8. PubMed ID: 16893541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diabetic eye: associated diseases, drugs in clinic, and role of self-assembled carriers in topical treatment.
    Kattar A; Concheiro A; Alvarez-Lorenzo C
    Expert Opin Drug Deliv; 2021 Nov; 18(11):1589-1607. PubMed ID: 34253138
    [No Abstract]   [Full Text] [Related]  

  • 57. Synthetic melatoninergic ligands: achievements and prospects.
    Kostiuk NV; Belyakova MB; Leshchenko DV; Zhigulina VV; Miniaev MV
    ISRN Biochem; 2014; 2014():843478. PubMed ID: 25937968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The association between nuclear receptors and ocular diseases.
    Liu K; Zou C; Qin B
    Oncotarget; 2017 Apr; 8(16):27603-27615. PubMed ID: 28187442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Melatonin: does it have utility in the treatment of haematological neoplasms?
    Li T; Yang Z; Jiang S; Di W; Ma Z; Hu W; Chen F; Reiter RJ; Yang Y
    Br J Pharmacol; 2018 Aug; 175(16):3251-3262. PubMed ID: 28880375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A New Insight of Herbal Promises Against Ocular Disorders: An Occuloinformatics Approach.
    Srivastava P; Tiwari A
    Curr Top Med Chem; 2016; 16(6):634-54. PubMed ID: 26286213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.